Publications

Golparian D, Jacobsson S, Sanchez-Buso L, Bazzo ML, Lan PT, Galarza P, Ohnishi M, and Unemo M

GyrB in silico mining in 27,151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility

Journal of Antimicrobial Chemotherapy (2022)

Karlowsky JA, Hackel MA, McLeod SM, and Miller AA

In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021

Antimicrobial Agents and Chemotherapy (2022)

Jacobsson S, Golparian D, Oxelbark J, Franceschi F, Brown D, Louie A, Drusano G and Unemo M

Pharmacodynamic evaluation of zoliflodacin treatment of Neisseria gonorrhoeae strains with amino acid substitutions in the zoliflodacin target GyrB using a dynamic hollow fiber infection model

Frontiers in Pharmacology (2022)

Newman LM, Kankam M, Nakamura A, Conrad T, Mueller J, O'Donnell J, Osborn BL, Gu K, Saviolakis GA

Thorough QT study to evaluate the effect of zoliflodacin, a novel therapeutic for gonorrhea, on cardiac repolarization in healthy adults

Antimicrobial Agents and Chemotherapy (2021)

Unemo M, Ahlstrand J, Sanchez-Buso, Day M, Aanensen D, Golparian D, Jacobsson S, Cole MJ and European Collaborative Group

High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018

Journal of Antimicrobial Chemotherapy (2021)

Jacobsson S, Kularatne R, Kittiyaowamarn R, Maseko V, Paopang P, Sangprasert P, Sirivongrangson P, Piddock L, Wi T, Alirol E, and Unemo M

High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South America (2015-2017)

Antimicrobial Agents and Chemotherapy (2019)

Durand-Reville TF, Miller AA, O’Donnell JP, Wu X, Sylvester MA, Guler S, Iyer R, Shapiro AB, Carter NM, Velez-Vega C, Moussa SH, McLeod SM, Chen A, Tanudra AM, Zhang J, Comita-Prevoir J, Romero JA, Huynh H, Ferguson AD, Horanyi PS, Mayclin SJ, Heine HS, Drusano GL, Cummings JE, Slayden RA, and Tommasi RA

Rational design of a new antibiotic class for drug-resistant infections

Nature (2021)

Shapiro AB, Moussa SH, McLeod SM, Durand-Reville T and Miller AA

Durlobactam, a new diazabicyclooctane β-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam

Frontiers in Microbiology (2021)

Jacobsson S, Golparian D, Oxelbark J, Alirol FF, Gustafsson TN, Brown D, Louie A, Drusano G and Unemo M

Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for zoliflodacin against Neisseria gonorrhoeae in a dynamic hollow fiber infection model

Frontiers in Pharmacology (2021)

O'Donnell J, Maloney K, Steidler M, Morrison R and Isaacs R

A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects

Clinical and Translational Science (2021)